Peijia Medical Ltd. (HK:9996)
:9996
Want to see HK:9996 full AI Analyst Report?
Top Page
Peijia Medical Ltd.
(9996)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$6.50
▼(-0.15% Downside)
Action:ReiteratedDate:04/28/26
The score is held back primarily by weak financial performance—ongoing losses and negative free cash flow despite improvements—while technicals provide modest support due to a mildly positive near-term trend. Valuation is not a clear positive because the negative P/E reflects lack of profitability and no dividend yield is provided.
Positive Factors
High gross margin (~67%)
Sustained ~67% gross margins give structural protection for profitability as volumes scale. High product-level margins support reinvestment in R&D, commercialization, and clinical evidence generation, enabling durable unit economics even with competitive pricing pressure.
Negative Factors
Persistent operating losses
Continued negative EBIT and ~-29% net margin indicate the company has not yet converted revenue growth into profitability. Prolonged operating losses can deplete capital, limit strategic options, and force cost-cutting that could slow commercialization and clinical adoption momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin (~67%)
Sustained ~67% gross margins give structural protection for profitability as volumes scale. High product-level margins support reinvestment in R&D, commercialization, and clinical evidence generation, enabling durable unit economics even with competitive pricing pressure.
Read all positive factors
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.43B
Dividend YieldN/A
Average Volume (3M)1.88M
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue Growth16.35%
EPS Growth9.43%
CountryHK
Employees1,047
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.22
Shares Outstanding672,060,670
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio1.54
Price to Book (P/B)1.95
Price to Sales (P/S)5.17
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.33Price Target Upside58.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$943.63M
Peijia Medical Ltd. Business Overview & Revenue Model
Company Description
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve rep...
How the Company Makes Money
Peijia Medical primarily makes money by selling medical devices used in interventional procedures, with revenue recognized from product sales to hospitals and other healthcare providers (often via distributors) in its target therapeutic areas (str...
Peijia Medical Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 694.42M | 615.48M | 441.13M | 250.83M | 136.53M |
| Gross Profit | 462.58M | 433.62M | 325.37M | 176.20M | 95.65M |
| EBITDA | -143.48M | -176.59M | -348.52M | -359.90M | -546.54M |
| Net Income | -198.03M | -226.58M | -392.52M | -407.81M | -574.22M |
Balance Sheet | |||||
| Total Assets | 2.66B | 2.69B | 2.67B | 3.32B | 3.16B |
| Cash, Cash Equivalents and Short-Term Investments | 610.52M | 712.52M | 942.92M | 1.74B | 2.30B |
| Total Debt | 434.22M | 253.40M | 221.13M | 131.88M | 7.63M |
| Total Liabilities | 799.05M | 644.11M | 397.88M | 678.86M | 144.48M |
| Stockholders Equity | 1.85B | 2.03B | 2.27B | 2.64B | 3.02B |
Cash Flow | |||||
| Free Cash Flow | -325.28M | -285.29M | -899.67M | -506.61M | -506.11M |
| Operating Cash Flow | -20.89M | -5.18M | -583.49M | -376.20M | -436.37M |
| Investing Cash Flow | -317.57M | -140.38M | -386.29M | -463.28M | -424.75M |
| Financing Cash Flow | 212.20M | 10.38M | 85.11M | 117.44M | 741.98M |
Peijia Medical Ltd. Technical Analysis
Positive
6.51
Price Trends
6.14
Positive
6.14
Positive
6.66
Positive
Market Momentum
0.28
Negative
68.89
Neutral
95.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9996, the sentiment is Positive. The current price of 6.51 is above the 20-day moving average (MA) of 6.24, above the 50-day MA of 6.14, and below the 200-day MA of 6.66, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 68.89 is Neutral, neither overbought nor oversold. The STOCH value of 95.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9996.
Peijia Medical Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$7.96B | 27.86 | 4.88% | 0.48% | 35.28% | 146.71% | |
71 Outperform | HK$7.71B | 19.30 | 9.39% | 1.88% | 29.94% | 119.16% | |
69 Neutral | HK$6.08B | 31.02 | 10.38% | 1.50% | 3.83% | -27.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$4.43B | -18.13 | -11.27% | ― | 16.35% | 9.43% | |
46 Neutral | HK$16.91B | 6.01 | 6.07% | ― | -3.62% | ― | |
43 Neutral | HK$3.29B | -4.06 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:9996
Peijia Medical Ltd.
6.38
1.26
24.61%
HK:0853
MicroPort Scientific
8.88
2.15
31.95%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
22.60
4.49
24.76%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
12.21
3.72
43.82%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.47
-2.03
-45.11%
HK:2172
MicroPort NeuroTech Limited
10.34
0.07
0.68%
Peijia Medical Ltd. Corporate Events
Peijia Medical Sets 2026 AGM to Approve Accounts, Board Changes and Share Issuance Mandate
Apr 23, 2026
Peijia Medical Limited has called its annual general meeting for May 29, 2026 in Suzhou, where shareholders will review and adopt the audited consolidated financial statements and directors’ and auditor’s reports for the year ended Dec...
Peijia Medical Marks First U.S. Implant in GeminiOne Heart Repair Trial
Apr 9, 2026
Peijia Medical has reported the successful first patient implant in a U.S. Food and Drug Administration early feasibility study of its GeminiOne Transcatheter Edge-to-Edge Repair system. The procedure was carried out by structural heart specialist...
Peijia Medical Chair and CEO to Boost Stake with HK$15 Million Share Purchase
Mar 25, 2026
Peijia Medical Limited reported that its chairman, chief executive officer and executive director, Dr. Yi Zhang, plans to increase his stake in the company by purchasing shares on the open market through a controlled corporation starting March 26,...
Peijia Medical Narrows Loss as TAVR and Neurointerventional Sales Accelerate in 2025
Mar 25, 2026
Peijia Medical Limited reported audited 2025 results showing revenue of RMB712.9 million, up 15.8% year-on-year, with a stable mix of 40.7% from transcatheter aortic valve replacement products and 59.3% from neurointerventional devices. The compan...
Peijia Medical Wins First U.S. FDA Clearance for DCwire Micro Guidewire
Mar 17, 2026
Peijia Medical Limited announced that its subsidiary Achieva Medical Limited has obtained U.S. FDA 510(k) clearance for the DCwire Micro Guidewire, the first product from the Group to receive FDA clearance. The approval marks a significant milesto...
Peijia Medical Sets March Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Mar 13, 2026
Peijia Medical Limited has scheduled a board meeting for March 25, 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025, and to authorize their publication. The board will...
Peijia Medical Files for EU MDR CE Mark for GeminiOne Mitral Repair Device
Feb 9, 2026
Peijia Medical has submitted an EU Medical Device Regulation CE Mark registration application for its GeminiOne Transcatheter Edge-to-Edge Repair system, developed for the treatment of mitral regurgitation, in partnership with France-based HighLif...
Peijia Medical Posts Double-Digit 2025 Revenue Growth on Neurovascular and TAVR Expansion
Feb 5, 2026
Peijia Medical reported unaudited 2025 revenue of approximately RMB700 million to RMB720 million, up about 13.7% to 17% from 2024, driven by strong growth across all three neurointerventional product lines and rising penetration in China’s T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.